Posted by Michael Wonder on 12 Aug 2024
FDA approves Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adults
12 August 2024 - Ascendis Pharma today announced that the US FDA has approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults.
Yorvipath is a prodrug of parathyroid hormone, administered once daily, designed to provide continuous exposure to released PTH over the 24 hour dosing period.
